Login to Your Account



Clinical Data Lands Buyout as Forest Makes $1.2B Viibryd Bet

By Jennifer Boggs


Wednesday, February 23, 2011
Buyout speculation fueled by the late January approval of depression drug Viibryd (vilazodone) – not to mention last week's chatter after President and CEO Drew Fromkin cancelled his presentation at BIO CEO – ended Tuesday with a resounding thud, as Clinical Data Inc. disclosed an offer much lower than its bullish analysts had expected.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription